Blood Product (Donor) Noninfectious and Infectious Testing and Modification

Area of Science:

• Transfusion Medicine
• Public Health
• Infectious Disease Control

Background:

• Blood transfusion safety is a critical public health concern.
• The U.S. blood supply is highly regulated, encompassing the entire safety value chain.
• Minimizing transfusion-associated risks requires optimization at every stage, from donor selection to post-transfusion surveillance.

Purpose of the Study:

• To provide an overview of blood donor infectious and noninfectious testing in the United States.
• To highlight the multifaceted nature of blood transfusion safety.
• To introduce pathogen inactivation as a key strategy for enhancing blood product safety.

Main Methods:

• Review of current practices in blood donor selection and testing in the U.S.
• Discussion of regulatory frameworks governing the U.S. blood supply.
• Exploration of pathogen inactivation technologies and their role in blood safety.

Main Results:

• The U.S. employs comprehensive testing for infectious and noninfectious agents in blood donors.
• Pathogen inactivation offers a significant advancement in reducing transfusion-related risks, including bacterial contamination and viral/parasitic infections.
• Continuous optimization across the blood safety value chain is essential for risk minimization.

Conclusions:

• Rigorous donor testing and advanced technologies like pathogen inactivation are crucial for maintaining a safe blood supply in the U.S.
• A holistic approach to blood safety, addressing all components from donor recruitment to post-transfusion monitoring, is paramount.
• Ongoing vigilance and implementation of safety measures are necessary to mitigate risks from known and emerging pathogens.